QRX-3: Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Study summary
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Eligibility
Sex
ALL
Min age
10 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Hospitalized patients
* presence of Acute renal failure
* Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \>2%
* willingness to participate
Exclusion Criteria:
High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status
Primary outcome measure(s)
Rate of change in creatinine glomerular filtration rate — 28 days compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.